Stocks Health care MANE
NYSE · Health careVeradermics, Inc (MANE)
It posted a net loss of $70M. In fiscal 2025 capital spending exceeded operating cash flow by $71.6M. At June 30, 2026 it held $319.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Veradermics, Inc does
Veradermics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MANE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$70M | -$111.91 | -$71.6M |
| 2025 | n/a | -$26.5M | -$37.05 | -$23.7M |
Latest SEC filings
What Veradermics, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 21, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- August 7, 2026IPO registration S-1
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about MANE
What does Veradermics, Inc do?
Veradermics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MANE.
Is Veradermics, Inc profitable?
No. In fiscal 2025 it reported a net loss of $70M.
When did Veradermics, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Follow MANE
Get an email when Veradermics, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow MANE: get an email when it filesWhere the numbers come from
Financial figures are the values Veradermics, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.